The Company


Lumigenex (Suzhou) Co. Ltd. is a biotechnology company based on functionalized nanomaterials,  including R&D and production of in vitro diagnostic products and infection control products and sales. We dedicate to the development of proprietary technologies that meet the ever increasing demands on clinical diagnostics. Lumigenex focuses on developing cost-effective rapid diagnostic products based on our patented Time Resolved Fluorescence Immunoassay (TRFIA) platform with primary areas of interests in cardiology, women's health, infectious disease, oncology and drugs of abuse. The self-developed time-resolved fluorescent immunoassay analyzer and its various POCT reagents have been improved in sensitivity and accuracy.

The company has a 100,000-level purification plant. It also passed CE, ISO13485 quality control system certification, obtained Class II medical device and Class III diagnostic reagent production licenses, 26 product registration certificates, 16 authorized patents and 22 trademarks. Four global invention patents were obtained through strategic cooperation with Kimberly-Clark. 

Closely collaborating with our global strategic partners, Lumigenex is committed to becoming a worldwide leader in the fields of quantitative POCT.


Attitude earns respect, innovation brightens future.

 [Core Value]
Take the customers as the center, relying on the strivers, adhering to hard work for a long time.

Mar. 2014

CFDA approvals for five immunoassay reagents adaptable to most chemical analyzers were obtained

Feb. 2014

CFDA approvals for time-resolved fluorescence immunochromatographic analyzer were obtained

Sep. 2013

Lumigenex passed The first Food and Drug Administration by the Suzhou Municipal Quality Management System Assessment